Loading…
What Is the Most Appropriate Induction Regimen for the Treatment of HIV-Associated Cryptococcal Meningitis When the Recommended Regimen Is Not Available? Evidence From a Network Meta-Analysis
Our object was to find the most appropriate, most effective, and most readily available of four induction regimens for HIV-associated cryptococcal meningitis (CM) (Regimen A: 1 week of AmB plus 5-FC followed by 1 week of fluconazole, Regimen B: 1 week of AmB plus fluconazole followed by 1 week of fl...
Saved in:
Published in: | Frontiers in pharmacology 2020-06, Vol.11, p.963-963 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c462t-8971991ed0b29740a71819e7c2c068e514f3081f4edbf86de6280aee7525613c3 |
---|---|
cites | cdi_FETCH-LOGICAL-c462t-8971991ed0b29740a71819e7c2c068e514f3081f4edbf86de6280aee7525613c3 |
container_end_page | 963 |
container_issue | |
container_start_page | 963 |
container_title | Frontiers in pharmacology |
container_volume | 11 |
creator | Li, Yao Huang, Xiaojie Qin, Yuanyuan Wu, Hao Yan, Xiaofeng Chen, Yaokai |
description | Our object was to find the most appropriate, most effective, and most readily available of four induction regimens for HIV-associated cryptococcal meningitis (CM) (Regimen A: 1 week of AmB plus 5-FC followed by 1 week of fluconazole, Regimen B: 1 week of AmB plus fluconazole followed by 1 week of fluconazole, Regimen C: 2 weeks of AmB plus 5-FC, Regimen D: 2 weeks of AmB plus fluconazole), given the vast differences between resource-limited and resource-abundant settings regarding therapeutic drug accessibility, availability, and affordability for HIV-associated (CM).
We conducted a network meta-analysis to compare the therapeutic efficacy and safety of four different induction treatment regimens.
The 10-week mortality of Regimen A was significantly lower than that of Regimen B and D, and the 2-week mortality of Regimen A was significantly lower than that of Regimen B. Furthermore, there were no statistically significant differences in 10-week mortality, 2-week mortality, as well as in effective fungicidal activity (EFA) over the first 2 weeks among Regimens B, C, and D. The statistical differences in adverse events between Regimen B and Regimen D, and Regimen C and Regimen D were not calculated to be significant.
Our results indicate that, 1 week of AmB plus 5-FC followed by 1 week of fluconazole is superior to the three other studied regimens, and that when 5-FC is not available, accessible, or affordable, 2 weeks of AmB plus fluconazole or 1 week of AmB plus fluconazole followed by 1 week of fluconazole is an appropriate substitution for 2 weeks of AmB plus 5-FC. |
doi_str_mv | 10.3389/fphar.2020.00963 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_eae0d32f177e416babe00f5ce8de9691</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_eae0d32f177e416babe00f5ce8de9691</doaj_id><sourcerecordid>2427523912</sourcerecordid><originalsourceid>FETCH-LOGICAL-c462t-8971991ed0b29740a71819e7c2c068e514f3081f4edbf86de6280aee7525613c3</originalsourceid><addsrcrecordid>eNpVkstu2zAQRYWiQROk2XdVcNmNXD5kSty0MIykEZAHEKTNkqDIkc1UElWSduGv66-VspMg4YbE8N4zg8HNsk8EzxirxNd2XCs_o5jiGcaCs3fZCeGc5aIi9P2r93F2FsIjTocJwXjxITtmtCQFqcRJ9u9hrSKqA4prQNcuRLQYR-9Gb1UEVA9mo6N1A7qDle1hQK3ze-m9BxVTISLXosv6V74IwenJZNDS78botNNadegaBjusbLQBPawTYDLfgXZ9MpskfganEW5c6r5VtlNNB9_R-dYaGDSgC-96pNANxL_O_07EqPLFoLpdsOFjdtSqLsDZ032a_bw4v19e5le3P-rl4irXBacxr0RJhCBgcENFWWBVkooIKDXVmFcwJ0XLcEXaAkzTVtwApxVWAOWczjlhmp1m9YFrnHqUaT298jvplJX7gvMrqXy0ugMJCrBhtCVlCQXhjWoA43auoTIguCCJ9e3AGjdND0anLXrVvYG-_RnsWq7cVpasKBilCfDlCeDdnw2EKHsbNHSdGsBtgqQFTYMzQSYpPki1dyF4aF_aECynGMl9jOQUI7mPUbJ8fj3ei-E5NOw_ErTHcA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2427523912</pqid></control><display><type>article</type><title>What Is the Most Appropriate Induction Regimen for the Treatment of HIV-Associated Cryptococcal Meningitis When the Recommended Regimen Is Not Available? Evidence From a Network Meta-Analysis</title><source>PubMed Central</source><creator>Li, Yao ; Huang, Xiaojie ; Qin, Yuanyuan ; Wu, Hao ; Yan, Xiaofeng ; Chen, Yaokai</creator><creatorcontrib>Li, Yao ; Huang, Xiaojie ; Qin, Yuanyuan ; Wu, Hao ; Yan, Xiaofeng ; Chen, Yaokai</creatorcontrib><description>Our object was to find the most appropriate, most effective, and most readily available of four induction regimens for HIV-associated cryptococcal meningitis (CM) (Regimen A: 1 week of AmB plus 5-FC followed by 1 week of fluconazole, Regimen B: 1 week of AmB plus fluconazole followed by 1 week of fluconazole, Regimen C: 2 weeks of AmB plus 5-FC, Regimen D: 2 weeks of AmB plus fluconazole), given the vast differences between resource-limited and resource-abundant settings regarding therapeutic drug accessibility, availability, and affordability for HIV-associated (CM).
We conducted a network meta-analysis to compare the therapeutic efficacy and safety of four different induction treatment regimens.
The 10-week mortality of Regimen A was significantly lower than that of Regimen B and D, and the 2-week mortality of Regimen A was significantly lower than that of Regimen B. Furthermore, there were no statistically significant differences in 10-week mortality, 2-week mortality, as well as in effective fungicidal activity (EFA) over the first 2 weeks among Regimens B, C, and D. The statistical differences in adverse events between Regimen B and Regimen D, and Regimen C and Regimen D were not calculated to be significant.
Our results indicate that, 1 week of AmB plus 5-FC followed by 1 week of fluconazole is superior to the three other studied regimens, and that when 5-FC is not available, accessible, or affordable, 2 weeks of AmB plus fluconazole or 1 week of AmB plus fluconazole followed by 1 week of fluconazole is an appropriate substitution for 2 weeks of AmB plus 5-FC.</description><identifier>ISSN: 1663-9812</identifier><identifier>EISSN: 1663-9812</identifier><identifier>DOI: 10.3389/fphar.2020.00963</identifier><identifier>PMID: 32714189</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>antifungal regimen ; cryptococcal meningitis ; HIV ; induction treatment ; network meta-analysis ; Pharmacology</subject><ispartof>Frontiers in pharmacology, 2020-06, Vol.11, p.963-963</ispartof><rights>Copyright © 2020 Li, Huang, Qin, Wu, Yan and Chen.</rights><rights>Copyright © 2020 Li, Huang, Qin, Wu, Yan and Chen 2020 Li, Huang, Qin, Wu, Yan and Chen</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c462t-8971991ed0b29740a71819e7c2c068e514f3081f4edbf86de6280aee7525613c3</citedby><cites>FETCH-LOGICAL-c462t-8971991ed0b29740a71819e7c2c068e514f3081f4edbf86de6280aee7525613c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7344322/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7344322/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32714189$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Yao</creatorcontrib><creatorcontrib>Huang, Xiaojie</creatorcontrib><creatorcontrib>Qin, Yuanyuan</creatorcontrib><creatorcontrib>Wu, Hao</creatorcontrib><creatorcontrib>Yan, Xiaofeng</creatorcontrib><creatorcontrib>Chen, Yaokai</creatorcontrib><title>What Is the Most Appropriate Induction Regimen for the Treatment of HIV-Associated Cryptococcal Meningitis When the Recommended Regimen Is Not Available? Evidence From a Network Meta-Analysis</title><title>Frontiers in pharmacology</title><addtitle>Front Pharmacol</addtitle><description>Our object was to find the most appropriate, most effective, and most readily available of four induction regimens for HIV-associated cryptococcal meningitis (CM) (Regimen A: 1 week of AmB plus 5-FC followed by 1 week of fluconazole, Regimen B: 1 week of AmB plus fluconazole followed by 1 week of fluconazole, Regimen C: 2 weeks of AmB plus 5-FC, Regimen D: 2 weeks of AmB plus fluconazole), given the vast differences between resource-limited and resource-abundant settings regarding therapeutic drug accessibility, availability, and affordability for HIV-associated (CM).
We conducted a network meta-analysis to compare the therapeutic efficacy and safety of four different induction treatment regimens.
The 10-week mortality of Regimen A was significantly lower than that of Regimen B and D, and the 2-week mortality of Regimen A was significantly lower than that of Regimen B. Furthermore, there were no statistically significant differences in 10-week mortality, 2-week mortality, as well as in effective fungicidal activity (EFA) over the first 2 weeks among Regimens B, C, and D. The statistical differences in adverse events between Regimen B and Regimen D, and Regimen C and Regimen D were not calculated to be significant.
Our results indicate that, 1 week of AmB plus 5-FC followed by 1 week of fluconazole is superior to the three other studied regimens, and that when 5-FC is not available, accessible, or affordable, 2 weeks of AmB plus fluconazole or 1 week of AmB plus fluconazole followed by 1 week of fluconazole is an appropriate substitution for 2 weeks of AmB plus 5-FC.</description><subject>antifungal regimen</subject><subject>cryptococcal meningitis</subject><subject>HIV</subject><subject>induction treatment</subject><subject>network meta-analysis</subject><subject>Pharmacology</subject><issn>1663-9812</issn><issn>1663-9812</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkstu2zAQRYWiQROk2XdVcNmNXD5kSty0MIykEZAHEKTNkqDIkc1UElWSduGv66-VspMg4YbE8N4zg8HNsk8EzxirxNd2XCs_o5jiGcaCs3fZCeGc5aIi9P2r93F2FsIjTocJwXjxITtmtCQFqcRJ9u9hrSKqA4prQNcuRLQYR-9Gb1UEVA9mo6N1A7qDle1hQK3ze-m9BxVTISLXosv6V74IwenJZNDS78botNNadegaBjusbLQBPawTYDLfgXZ9MpskfganEW5c6r5VtlNNB9_R-dYaGDSgC-96pNANxL_O_07EqPLFoLpdsOFjdtSqLsDZ032a_bw4v19e5le3P-rl4irXBacxr0RJhCBgcENFWWBVkooIKDXVmFcwJ0XLcEXaAkzTVtwApxVWAOWczjlhmp1m9YFrnHqUaT298jvplJX7gvMrqXy0ugMJCrBhtCVlCQXhjWoA43auoTIguCCJ9e3AGjdND0anLXrVvYG-_RnsWq7cVpasKBilCfDlCeDdnw2EKHsbNHSdGsBtgqQFTYMzQSYpPki1dyF4aF_aECynGMl9jOQUI7mPUbJ8fj3ei-E5NOw_ErTHcA</recordid><startdate>20200630</startdate><enddate>20200630</enddate><creator>Li, Yao</creator><creator>Huang, Xiaojie</creator><creator>Qin, Yuanyuan</creator><creator>Wu, Hao</creator><creator>Yan, Xiaofeng</creator><creator>Chen, Yaokai</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20200630</creationdate><title>What Is the Most Appropriate Induction Regimen for the Treatment of HIV-Associated Cryptococcal Meningitis When the Recommended Regimen Is Not Available? Evidence From a Network Meta-Analysis</title><author>Li, Yao ; Huang, Xiaojie ; Qin, Yuanyuan ; Wu, Hao ; Yan, Xiaofeng ; Chen, Yaokai</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c462t-8971991ed0b29740a71819e7c2c068e514f3081f4edbf86de6280aee7525613c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>antifungal regimen</topic><topic>cryptococcal meningitis</topic><topic>HIV</topic><topic>induction treatment</topic><topic>network meta-analysis</topic><topic>Pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Yao</creatorcontrib><creatorcontrib>Huang, Xiaojie</creatorcontrib><creatorcontrib>Qin, Yuanyuan</creatorcontrib><creatorcontrib>Wu, Hao</creatorcontrib><creatorcontrib>Yan, Xiaofeng</creatorcontrib><creatorcontrib>Chen, Yaokai</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Yao</au><au>Huang, Xiaojie</au><au>Qin, Yuanyuan</au><au>Wu, Hao</au><au>Yan, Xiaofeng</au><au>Chen, Yaokai</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>What Is the Most Appropriate Induction Regimen for the Treatment of HIV-Associated Cryptococcal Meningitis When the Recommended Regimen Is Not Available? Evidence From a Network Meta-Analysis</atitle><jtitle>Frontiers in pharmacology</jtitle><addtitle>Front Pharmacol</addtitle><date>2020-06-30</date><risdate>2020</risdate><volume>11</volume><spage>963</spage><epage>963</epage><pages>963-963</pages><issn>1663-9812</issn><eissn>1663-9812</eissn><abstract>Our object was to find the most appropriate, most effective, and most readily available of four induction regimens for HIV-associated cryptococcal meningitis (CM) (Regimen A: 1 week of AmB plus 5-FC followed by 1 week of fluconazole, Regimen B: 1 week of AmB plus fluconazole followed by 1 week of fluconazole, Regimen C: 2 weeks of AmB plus 5-FC, Regimen D: 2 weeks of AmB plus fluconazole), given the vast differences between resource-limited and resource-abundant settings regarding therapeutic drug accessibility, availability, and affordability for HIV-associated (CM).
We conducted a network meta-analysis to compare the therapeutic efficacy and safety of four different induction treatment regimens.
The 10-week mortality of Regimen A was significantly lower than that of Regimen B and D, and the 2-week mortality of Regimen A was significantly lower than that of Regimen B. Furthermore, there were no statistically significant differences in 10-week mortality, 2-week mortality, as well as in effective fungicidal activity (EFA) over the first 2 weeks among Regimens B, C, and D. The statistical differences in adverse events between Regimen B and Regimen D, and Regimen C and Regimen D were not calculated to be significant.
Our results indicate that, 1 week of AmB plus 5-FC followed by 1 week of fluconazole is superior to the three other studied regimens, and that when 5-FC is not available, accessible, or affordable, 2 weeks of AmB plus fluconazole or 1 week of AmB plus fluconazole followed by 1 week of fluconazole is an appropriate substitution for 2 weeks of AmB plus 5-FC.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>32714189</pmid><doi>10.3389/fphar.2020.00963</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1663-9812 |
ispartof | Frontiers in pharmacology, 2020-06, Vol.11, p.963-963 |
issn | 1663-9812 1663-9812 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_eae0d32f177e416babe00f5ce8de9691 |
source | PubMed Central |
subjects | antifungal regimen cryptococcal meningitis HIV induction treatment network meta-analysis Pharmacology |
title | What Is the Most Appropriate Induction Regimen for the Treatment of HIV-Associated Cryptococcal Meningitis When the Recommended Regimen Is Not Available? Evidence From a Network Meta-Analysis |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T15%3A28%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=What%20Is%20the%20Most%20Appropriate%20Induction%20Regimen%20for%20the%20Treatment%20of%20HIV-Associated%20Cryptococcal%20Meningitis%20When%20the%20Recommended%20Regimen%20Is%20Not%20Available?%20Evidence%20From%20a%20Network%20Meta-Analysis&rft.jtitle=Frontiers%20in%20pharmacology&rft.au=Li,%20Yao&rft.date=2020-06-30&rft.volume=11&rft.spage=963&rft.epage=963&rft.pages=963-963&rft.issn=1663-9812&rft.eissn=1663-9812&rft_id=info:doi/10.3389/fphar.2020.00963&rft_dat=%3Cproquest_doaj_%3E2427523912%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c462t-8971991ed0b29740a71819e7c2c068e514f3081f4edbf86de6280aee7525613c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2427523912&rft_id=info:pmid/32714189&rfr_iscdi=true |